PL9643
Peptide
Evidence outlook · lead readout
MELODY-1 (NCT05201170) · Dry Eye
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
MELODY-1 (NCT05201170): The trial was randomized, quadruple-blinded, vehicle-controlled, and large enough to be adequately powered, with hard clinical/objective dry eye measures (corneal staining and ocular pain) as co-primary endpoints -- a strong design overall. However, an outside source indicates that neither co-primary endpoint reached statistical significance, so the study did not demonstrate the treatment effect it was designed to show, which keeps this as a well-designed but inconclusive trial rather than strong positive evidence.
Result from the company press release; the only significant pain result comes from an analysis adjusted after the planned one.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
MELODY-1 NCT05201170 · Dry Eye The trial was randomized, quadruple-blinded, vehicle-controlled, and large enough to be adequately powered, with hard clinical/objective dry eye measures (corneal staining and ocular pain) as co-primary endpoints -- a strong design overall. However, an outside source indicates that neither co-primary endpoint reached statistical significance, so the study did not demonstrate the treatment effect it was designed to show, which keeps this as a well-designed but inconclusive trial rather than strong positive evidence. Result from the company press release; the only significant pain result comes from an analysis adjusted after the planned one. Registry: NCT05201170 | 3 | Conjunctival Sum Lissamine Green Staining (Visit 6 (Day 85), Change from Pre-CAE to Post-CAE); Ocular Pain (Change from Pre-CAE to Post-CAE at Visit 6 (Day 85)) 2023-09-01 | Co-primary sign endpoint (lissamine green staining) did not achieve statistical significance; in the unadjusted planned analyses neither co-primary reached significance | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Competitive landscape
This drug's own stage for Dry Eye Disease: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| PL9643: this drug | Phase 3 | Peptide | Melanocortin receptors | Partial signal | NCT05201170: Co-primary sign endpoint (lissamine green staining) did not achieve statistical significance; in the unadjusted planned analyses neither co-primary reached significance missed | |
| Cyclosporine (Vevye) | Approved | Small molecule | Calcineurin | Partial signal | No reviewed efficacy summary in this indication | |
| Reproxalap | Phase 3 | Small molecule | Reactive aldehyde species (RASP) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent